Ameritas Investment Partners’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Ameritas Investment Partners’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8	Closed	-$10K	–	3202
2022 Q1	$10K	Hold	8	–	–	﹤0.01%	2800
2021 Q4	$20K	Hold	8	–	–	﹤0.01%	2650
2021 Q3	$143K	Hold	8	–	–	0.01%	1466
2021 Q2	$83K	Buy	8 +1	+14%	+$8.38K	﹤0.01%	1854
2021 Q1	$50K	Hold	7	–	–	﹤0.01%	2086
2020 Q4	$39K	Hold	7	–	–	﹤0.01%	2130
2020 Q3	$69K	Hold	7	–	–	﹤0.01%	1649
2020 Q2	$64K	Buy	7 +2	+40%	+$18.3K	﹤0.01%	1687
2020 Q1	$45K	Hold	5	–	–	﹤0.01%	1728
2019 Q4	$55K	Buy	5 +4	+400%	+$24.1K	﹤0.01%	1866
2019 Q3	$6K	Hold	1	–	–	﹤0.01%	2902
2019 Q2	$11K	Buy	+1	New	+$5.97K	﹤0.01%	2770

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Ameritas Investment Partners's IRLA Position: Q2 2022 in Review

Ameritas Investment Partners sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2022, closing a stake of 8 shares — an estimated $10K sold.

Ameritas Investment Partners first reported a position in IRLA in Q2 2019 and held it in 12 quarters. The position peaked at $143K in Q3 2021. 66 funds tracked by Wall St. Rank hold IRLA as of Q2 2022.

Ameritas Investment Partners reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Ameritas Investment Partners sold 8 IRulya Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $10K.
Ameritas Investment Partners first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2019 and held it in 12 quarters.
Ameritas Investment Partners's IRulya Therapeutics Inc. Common Stock position peaked at $143K in Q3 2021.
66 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.